Cevenfacta
What Cevenfacta is used for
CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. … (the exact criteria are in the official EMA product information).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Cevenfacta
- Active substance
- eptacog beta (activated)
- Disease area
- Hemophilia A; Hemophilia B
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD08
- Marketing authorisation holder
- Laboratoire Francais du Fractionnement et des Biotechnologies
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cevenfacta used for?
CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. … (the exact criteria are in the official EMA product information).
What is the active substance in Cevenfacta?
Cevenfacta contains eptacog beta (activated).
Who makes Cevenfacta?
The EU marketing authorisation holder is Laboratoire Francais du Fractionnement et des Biotechnologies.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU